window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Ochre Bio

  • Drug Discovery & Development,Genomics and sequencing,Pharmaceuticals and therapeutics,Therapeutic Areas

    Ochre Bio and GSK complete research phase with large-scale human liver genomics datasets

    Ochre Bio has completed the research phase of its collaboration [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development

    Ochre Bio founder takes helm as CEO to drive RNA liver therapies towards clinic

    RNA therapeutics biotech Ochre Bio has appointed its founder and [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Ochre Bio appoints pharma veteran Elaine Sullivan as senior independent director

    RNA therapeutics developer Ochre Bio has appointed Dr Elaine Sullivan [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • VIVEbiotech expands in vivo lentiviral vector portfolio to 15 programmes
    Categories: Advanced Therapies, Biotech & Pharma Business, Manufacturing & Supply Chain
  • Oryzon reports strong early AML response data from iadademstat combinations at EHA 2026
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Sygnature Discovery partners with DaltonTx to expand AI drug discovery capabilities
    Categories: Digital & Data, Drug Discovery & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top